Semaglutide
Ozempic · Wegovy · Rybelsus
A GLP-1 receptor agonist with FDA approval for type 2 diabetes and obesity, demonstrating unprecedented weight loss results in clinical trials.
Half-Life
~1 week
MW
4113.6 Da
Amino Acids
31 AA
Evidence
High Evidence
Regulatory Status
FDA-approved (Ozempic: T2D, Wegovy: obesity, Rybelsus: T2D oral). Widely prescribed.
In Plain English
A once-weekly injection that mimics the GLP-1 gut hormone — tells your brain you're full and tells your pancreas to release insulin when blood sugar rises. The active compound in Ozempic (diabetes) and Wegovy (weight loss).
Overview
Semaglutide is a GLP-1 receptor agonist with 94% homology to native human GLP-1. Available as weekly injection (Ozempic for diabetes, Wegovy for obesity) and daily oral (Rybelsus). Clinical trials demonstrated up to 15-17% body weight reduction, revolutionizing obesity treatment.
Common Formats
- Pre-filled injectable pen (weekly)
- Oral tablet
- Compounded injectable
Storage Notes
Refrigerate 2-8°C before first use. After first use, room temperature or refrigerator for 56 days (injectable).
Looking for multi-compound protocols?
Browse educational protocol discussions that include Semaglutide.
Related Compounds
Tirzepatide
A dual GIP/GLP-1 receptor agonist with FDA approval showing up to 22% weight loss — superior to semaglutide in head-to-head trials.
Liraglutide
A once-daily GLP-1 receptor agonist with FDA approval for T2D and obesity, the predecessor to semaglutide with strong clinical evidence.
Retatrutide
A triple GIP/GLP-1/glucagon receptor agonist in Phase III trials, showing over 24% weight loss — potentially the most powerful metabolic peptide in development.
Educational Disclaimer: All information on this page is for educational and research purposes only. This does not constitute medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional.